Somewhat Positive Press Coverage Very Likely to Affect Insys Therapeutics (INSY) Share Price

News stories about Insys Therapeutics (NASDAQ:INSY) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Insys Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 83 out of 100, meaning that recent news coverage is very likely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

INSY has been the topic of several recent analyst reports. Royal Bank Of Canada set a $16.00 price target on shares of Insys Therapeutics and gave the company a “buy” rating in a report on Monday, March 27th. Zacks Investment Research cut shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 11th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Insys Therapeutics in a report on Thursday, March 16th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a report on Thursday, April 6th. Finally, Piper Jaffray Companies cut shares of Insys Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $20.00 to $10.00 in a report on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $13.50.

Insys Therapeutics (NASDAQ INSY) traded up 4.86% during mid-day trading on Tuesday, reaching $12.08. 509,457 shares of the company traded hands. Insys Therapeutics has a 52-week low of $8.70 and a 52-week high of $19.96. The stock has a 50 day moving average price of $12.19 and a 200-day moving average price of $10.90. The company’s market capitalization is $871.27 million.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $35.92 million during the quarter, compared to analysts’ expectations of $37.78 million. Insys Therapeutics had a negative return on equity of 0.97% and a negative net margin of 2.64%. The business’s revenue was down 40.5% on a year-over-year basis. During the same period last year, the business earned $0.11 earnings per share. Analysts expect that Insys Therapeutics will post ($0.48) EPS for the current fiscal year.

In related news, CEO Saeed Motahari acquired 4,500 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was bought at an average cost of $11.98 per share, with a total value of $53,910.00. Following the completion of the acquisition, the chief executive officer now owns 4,500 shares in the company, valued at $53,910. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Steven J. Meyer acquired 8,000 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were bought at an average cost of $12.21 per share, with a total value of $97,680.00. Following the completion of the acquisition, the director now owns 52,083 shares of the company’s stock, valued at approximately $635,933.43. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 21,900 shares of company stock valued at $268,090. Company insiders own 67.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Mideast Time and is owned by of Mideast Time. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.mideasttime.com/somewhat-positive-press-coverage-very-likely-to-affect-insys-therapeutics-insy-share-price/1797078.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:INSY”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.